Equillium Stock Soars 25.8% on Janus Henderson Stake and $50M EQ504 Funding

Introduction

Equillium, Inc. (ticker: EQ) is a clinical-stage biotechnology company listed on the NASDAQ. As of December 22, 2025, its shares were trading at $1.4472, representing a 25.84% increase on the day, with a volume of 835,458 shares. The company focuses on developing immunomodulatory therapeutics targeting severe autoimmune disorders.

Corporate Structure

Headquartered in La Jolla, California, Equillium was founded in 2017 and maintains a workforce of 11–50 employees. Its operations span the United States, Australia, and New Zealand. Leadership includes Bruce D. Steel as President and Chief Executive Officer, and Stephen Connelly, Ph.D., MBA, serving as Chief Scientific Officer and President. The Scientific Advisory Board includes Fred Ramsdell, a recipient of the Nobel Prize in Physiology or Medicine.

Biotechnology by Louis Reed

Recent Developments and News

On December 8, 2025, Janus Henderson Group PLC filed a Schedule 13G disclosing a 9.99% stake in Equillium’s common stock. Earlier, ADAR1 Capital Management reported beneficial ownership of 9.9% as of November 14, 2025, and Woodline Partners LP held 5.9% as of September 30, 2025.
In October 2024, Equillium closed the first tranche of an up to $50 million private placement, raising approximately $30 million in gross proceeds through the issuance of roughly 52.6 million shares or prefunded warrants, with the potential for an additional $20 million upon meeting clinical milestones. Leerink Partners acted as lead placement agent, with Mintz advising on the transaction.
In December 2022, Equillium entered into an exclusive option and asset purchase agreement with Ono Pharmaceutical Co., Ltd., under which Ono made an upfront payment of ¥3.5 billion and may pay up to ¥18 billion in milestone payments for the rights to itolizumab. During this period, research and development costs were to be fully reimbursed by Ono.
On November 5, 2025, management hosted a virtual KOL event that included discussions on targeting the Aryl Hydrocarbon Receptor in ulcerative colitis. Equillium also announced a revised treasury strategy to include digital currencies and secured up to $50 million from ADAR1 and Janus Henderson to advance its AhR modulator, EQ504, into a Phase 1 trial planned for mid-2026. Stephen Connelly was promoted to President in addition to his CSO role.

Financial and Strategic Analysis

According to Yahoo Finance, Equillium’s market capitalization was reported at approximately $70 million, with an enterprise value of $41 million. The company reported trailing twelve-month revenue of $4.39 million and a net loss of $24.42 million, yielding a diluted EPS of –$0.58. The profit margin was flat, return on assets was –44.17%, and return on equity was –90.24%. Total cash was reported at $33.12 million, with total debt representing 2.41% of equity. Leveraged free cash flow was reported at –$13.36 million. Valuation multiples included a price/sales ratio of 11.88 and price/book ratio of 2.38. Institutional ownership by Janus Henderson, ADAR1, and Woodline Partners suggests concentrated support, while private placements and the Ono partnership provide funding runway into 2025.

Market Position and Industry Context

Equillium operates in the specialty biotech segment, developing immunomodulatory agents for conditions with high unmet need. Itolizumab is currently in Phase 3 for acute graft-versus-host disease and Phase 1b for lupus nephritis; EQ101 is in Phase 2 for alopecia areata; EQ102 is in Phase 1 for celiac disease; and EQ504 is slated for Phase 1 initiation in mid-2026 targeting ulcerative colitis. The company’s beta of 1.92 indicates above-average share volatility, which is common for early-stage biotechnology firms. Its valuation reflects investor expectations of clinical milestones and partnerships, balanced against risks associated with trial outcomes and ongoing financing needs.

tl;dr

Equillium’s stock increased 25.84% to $1.4472 on December 22, 2025, following disclosures of near-10% stakes by Janus Henderson and ADAR1, along with confirmation of up to $50 million in financing to advance EQ504 into a Phase 1 trial in mid-2026. The Ono collaboration continues to support research and development for itolizumab, which is currently in Phase 3 for acute graft-versus-host disease. With $33 million in cash alongside new proceeds, the company is funded into 2025, pending Phase 3 readouts and EQ504 data in late 2026.